Funding for this research was provided by:
Janssen Research and Development, LLC, USA
Received: 4 February 2020
Accepted: 1 October 2020
First Online: 19 October 2020
Ethics approval and consent to participate
: The Institutional Review Board at each of the nine participating study sites approved the study protocol and subsequent amendments. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, consistent with Good Clinical Practices and applicable regulatory requirements. Participants, their parents (for participants < 18 years old), or legally authorized representatives provided written informed consent before joining the study. Participants also provided assent.
: Not applicable.
: Dzmitry A. Kaliukhovich, Nikolay V. Manyakov, Abigail Bangerter, Seth Ness, Andrew Skalkin (at the time of study conduct), and Gahan Pandina are employees of Janssen Research & Development, LLC and hold company stocks/stock options. Matthew Goodwin has received research and consulting funding from Janssen Research & Development, LLC. Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili, Inc., LabCorp, Inc., and Roche Pharmaceutical Company, a consultant for Apple, Inc, Gerson Lehrman Group, Guidepoint, Inc., Teva Pharmaceuticals, Tris Pharma, Inc., and Axial Ventures, has received grant funding from Janssen Research and Development, and is CEO of DASIO, LLC. Dawson has developed technology that has been licensed and Dawson and Duke University have benefited financially. Dawson receives royalties from Guilford Press, Springer, and Oxford University Press. Robert Hendren received reimbursement for consultation from Janssen Research & Development, LLC. Bennett Leventhal has received research grant funding from the NIH, is a consultant to Janssen Research and Development, LLC and the Illinois Children’s Healthcare Foundation, and is a board member of the Brain Research Foundation. Frederick Shic is on the Scientific Advisory Board of and is a consultant to Janssen Research and Development, LLC, and has received grant funding from Janssen Research and Development LLC, and Roche.
: Data from this study were submitted as an abstract and accepted for presentation at the 32<sup>nd</sup> ECNP Congress, September 8, 2019, Copenhagen, Denmark.